Thermo Fisher Scientific Inc. (TMO) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $469.31 (-2.00%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 9, 2026 | Daniel Arias | Stifel Nicolaus | $700.00 | +49.2% |
| Jan 5, 2026 | Vijay Kumar | Evercore ISI | $650.00 | +38.5% |
| Dec 9, 2025 | Evie Koslosky | Goldman Sachs | $685.00 | +46.0% |
| Dec 7, 2025 | Paul Knight | KeyBanc | $750.00 | +59.8% |
| Oct 2, 2025 | Luke Sergott | Barclays | $585.00 | +24.7% |
| Sep 2, 2025 | Conor McNamara | RBC Capital | $561.00 | +19.5% |
| Jul 8, 2025 | Dan Leonard | UBS | $460.00 | -2.0% |
| Apr 23, 2025 | Matthew Sykes | Goldman Sachs | $610.00 | +30.0% |
| Jan 31, 2025 | Conor McNamara | RBC Capital | $693.00 | +47.7% |
| Jan 2, 2025 | Vijay Kumar | Evercore ISI | $585.00 | +24.7% |
| Oct 24, 2024 | Catherine Schulte | Robert W. Baird | $622.00 | +32.5% |
| Oct 23, 2024 | Luke Sergott | Barclays | $610.00 | +30.0% |
| Oct 1, 2024 | Vijay Kumar | Evercore ISI | $630.00 | +34.2% |
| Sep 20, 2024 | Daniel Arias | Stifel Nicolaus | $680.00 | +44.9% |
| Sep 20, 2024 | Catherine Schulte | Robert W. Baird | $632.00 | +34.7% |
| Sep 19, 2024 | Patrick Donnelly | Citigroup | $620.00 | +32.1% |
| Sep 18, 2024 | Justin Bowers | Deutsche Bank | $630.00 | +34.2% |
| Sep 16, 2024 | Derik de Bruin | Bank of America Securities | $675.00 | +43.8% |
| Jul 25, 2024 | Andrew Cooper | Raymond James | $660.00 | +40.6% |
| Jun 28, 2024 | Luke Sergott | Barclays | $600.00 | +27.8% |
Top Analysts Covering TMO
TMO vs Sector & Market
| Metric | TMO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 14 | 8 | 18 |
| Target Upside | +39.5% | +1150.2% | +14.9% |
| P/E Ratio | 25.80 | 6.84 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $46.73B | $47.35B | $48.29B | 8 |
| 2027-03-28 | $11.62B | $11.74B | $11.87B | 3 |
| 2027-03-31 | $11.45B | $11.53B | $11.59B | 2 |
| 2027-06-28 | $12.17B | $12.29B | $12.43B | 3 |
| 2027-06-30 | $12.06B | $12.14B | $12.21B | 2 |
| 2027-09-28 | $12.38B | $12.50B | $12.64B | 3 |
| 2027-09-30 | $12.26B | $12.34B | $12.41B | 2 |
| 2027-12-28 | $13.57B | $13.70B | $13.86B | 3 |
| 2027-12-31 | $49.11B | $49.89B | $51.42B | 9 |
| 2028-03-28 | $12.33B | $12.46B | $12.60B | 2 |
| 2028-03-31 | $12.24B | $12.32B | $12.39B | 1 |
| 2028-06-28 | $12.97B | $13.10B | $13.25B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $24.57 | $24.76 | $25.96 | 7 |
| 2027-03-28 | $5.86 | $5.93 | $6.02 | 1 |
| 2027-03-31 | $5.79 | $5.84 | $5.88 | 1 |
| 2027-06-28 | $6.33 | $6.41 | $6.51 | 1 |
| 2027-06-30 | $6.36 | $6.42 | $6.46 | 1 |
| 2027-09-28 | $6.86 | $6.95 | $7.06 | 1 |
| 2027-09-30 | $6.80 | $6.86 | $6.91 | 1 |
| 2027-12-28 | $7.84 | $7.94 | $8.06 | 1 |
| 2027-12-31 | $26.69 | $27.11 | $28.54 | 8 |
| 2028-03-28 | $6.54 | $6.62 | $6.72 | 1 |
| 2028-03-31 | $6.56 | $6.62 | $6.67 | 2 |
| 2028-06-28 | $7.04 | $7.13 | $7.24 | 1 |
Frequently Asked Questions
What is the analyst consensus for TMO?
The consensus among 14 analysts covering Thermo Fisher Scientific Inc. (TMO) is Buy with an average price target of $650.58.
What is the highest price target for TMO?
The highest price target for TMO is $750.00, set by Paul Knight at KeyBanc on 2025-12-07.
What is the lowest price target for TMO?
The lowest price target for TMO is $460.00, set by Dan Leonard at UBS on 2025-07-08.
How many analysts cover TMO?
14 analysts have issued ratings for Thermo Fisher Scientific Inc. in the past 12 months.
Is TMO a buy or sell right now?
Based on 14 analyst ratings, TMO has a consensus rating of Buy (2.00/5) with a +39.5% upside to the consensus target of $650.58.
What are the earnings estimates for TMO?
Analysts estimate TMO will report EPS of $24.76 for the period ending 2026-12-31, with revenue estimated at $47.35B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.